Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi.
New York-based Formation Bio originally launched in 2016 under the name TrialSpark as a service provider that helped companies more rapidly enroll clinical trials. Its prior investors Sequoia, Thrive, Emerson Collective and Lachy Groom participated in the recent series D round along with new investors, including SV Angel Growth and FPV Ventures.
The round’s proceeds will support ongoing buildout of Formation’s AI capabilities as well as acquisition and licensing of clinical-stage drug...
<p>Executive Summary</p> <p>An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker</p>
China has seen a “milestone year for the overseas launch of domestically produced innovative drugs.”
Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.
An interactive look at pharma, medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
